ABSTRACT
Introduction: In a subset of Covid19-convalescent patients, a multitude of long-term sequelae are increasingly being reported. We report 4 cases with varying neuro-GI and motility manifestations after recent COVID-19 infection. Case Description/Methods: Case 1: A 23-year-old man contracted COVID-19 and had a protracted course of respiratory illness. Despite resolution of respiratory symptoms and dysgeusia, he continued to experience early satiety, postprandial nausea, vomiting and unintentional weight loss. Gastric Emptying Scan (GES) revealed gastroparesis (Figure A). Dietary modification and metoclopramide led to symptomatic improvement. Case 2: A 39-year-old woman with migraines, suffered from Covid-19 infection where anosmia and respiratory symptoms lasted for 2 weeks. Despite resolution of initial symptoms, she started experiencing nausea and vomiting, and reported stereotypical symptoms with complete absence of vomiting between episodes. Endoscopic examination, CT head and GES were normal. Urine tox screen was negative for cannabinoids. She responded favorably to amitriptyline and ondansetron. Case 3: A 47-year-old man started experiencing severe constipation associated with abdominal pain and bloating soon after being diagnosed with COVID-19. Three months after resolution of respiratory symptoms, in addition to constipation, he began reporting postprandial fullness, early satiation and epigastric pain. GES showed gastroparesis ( figure B) and a Sitzmarks Study revealed delayed colonic transit (Figure C). Prucalopride was started, leading to improvement in symptoms. Case 4: A 74-year-old woman with obesity and diabetes, was hospitalized and intubated for severe respiratory distress due to COVID-19. After discharge, she had persistent symptoms of brain fog, fatigue, dyspnea as well as diarrhea and abdominal cramping, persisting despite loperamide and dicyclomine. C. difficile toxin, random colonic biopsies and H2 breath test were unremarkable. Her symptoms eventually improved with rifaximin. Discussion(s): We report 4 cases with post-COVID gastroparesis, cyclical vomiting syndrome, pan-gut dysmotility, and post-infectious IBS phenotypes.The pathophysiology of post-infectious-gut-brain disorders is still obscure. The current conceptual framework implicates acquired neuropathy, altered motility, intestinal barrier disruption and persistent intestinal inflammation. Similar pathophysiology may be involved in COVID-19 infection leading to sustained neurogastroenterological dysfunction and gut dysmotility.
ABSTRACT
Introduction: Gastrointestinal tract involvement from herpes simplex virus is commonly associated with esophagitis. However, herpes simplex infection of the stomach is very rare with only a handful of cases being reported in immunocompromised patients. We present a case of herpes gastritis causing gastric outlet obstruction in an otherwise healthy, immunocompetent individual. Case Description/Methods: A 37-year-old male with a recent past medical history of COVID-19 infection, presented to the hospital with intractable nausea, vomiting, bloating, and early satiety for two days. Upon evaluation, CBC and CMP were remarkable for a WBC of 12.5 k/mm3 and ALT and AST of 124 U/L and 129 U/L, respectively. Lipase was 373 U/L. A CT abdomen/pelvis w/contrast showed circumferential wall thickening with edematous changes in the antrum consistent with localized inflammatory response. There was suspicion for gastric lymphoma and patient was admitted for further workup. An EGD was performed which showed exudative esophagitis and antral wall edema with luminal narrowing of gastric antrum. Endoscopic ultrasound (EUS) showed a 2.5 x 3 cm antral wall lesion worrisome for linitis plastica. Esophageal biopsies showed focal cytologic changes consistent with herpes esophagitis. The FNA of the gastric antral wall showed multinucleation of the basal cell layer with classic ground glass nuclei, consistent with herpes infection. No dysplasia or malignancy was seen. Both HSV1 and HSV2 IgG were elevated. HSV IgM was normal. A HSV PCR was ordered but never resulted. Patient was started on Valacyclovir 1 g PO BID for 10 days. He underwent a follow-up EGD 3 months later which showed complete resolution of the gastric antral changes (Figure). Discussion(s): Herpes gastritis is extremely rare. Literature review has revealed only 3 case reports of herpes gastritis;and all involved immunocompromised patients. To the best of our knowledge, this is the first case of herpes gastritis in an immunocompetent patient. Our patient presented with symptoms of gastric outlet obstruction which was caused by local inflammation from herpes simplex. It is unclear if having a COVID 19 infection altered patient's immunity and lead to herpes gastritis. This may need further investigation. No established guideline exists for treatment duration. Our patient received 10-day course of Valacyclovir, and his symptoms improved. Furthermore, patient had complete resolution of the herpes infection on follow-up EGD, indicating adequate treatment response.
ABSTRACT
BACKGROUND: The novel SARS-CoV-2 Coronavirus pandemic has had significant global impact on health care. The pandemic's effect on patients with inflammatory bowel disease (IBD) is unknown, and health care delivery to this largely immunocompromised population is of concern, as many patients refrained or were unable to seek in-person medical care. We noticed there was a decrease in IBD related Emergency Department (ED) visits. Thus, we aimed to explore if the pandemic influenced IBD specific search trends in the United States. We predicted more patients would search for symptoms or medications using Google in order to self-treat or self-care. METHOD(S): Using Google Trends (GT), we queried Crohn's Disease (CD) or Ulcerative Colitis (UC) in combination with IBD-related symptoms (i.e. bloating, rectal bleeding, abdominal pain and diarrhea) or medications (i.e. infliximab and prednisone) between January 1 and April 30 for the years 2018-2020 in the United States. Frequencies of the specific search terms were compared to the site's relative search volume over weekly and monthly intervals. IBD related ED visits were also collected from July 2018 to July 2020. Data was analyzed using monthly and weekly mean search scores compared across years and through 2020 using ANOVA with post-hoc Tukey adjustment for multiple comparisons. RESULT(S): There were decreased search scores for bloating and rectal bleeding with IBD terms occurring during March and April of 2020 compared to years prior but not abdominal pain or diarrhea. The bloating plus CD/UC queries saw the largest variation in 2020 (CD: F = 19.18 with (2,89) df, P < 0.0001, UC: F = 14.08 with (2,89) df, P < 0.0001). For April 2020, medication search terms for infliximab + UC were significantly decreased (F = 47.73 with (2,89) df, P < 0.0001) but not for infliximab + CD (F = 3.08 with (2,89) df, P = 0.051) Prednisone searches also significantly decreased with CD and UC during this time period. In terms of IBD related ER visits, there were 84 in 2018, 99 in 2019, and 15 in 2020. The average quarterly visits in the 30 months preceding Covid was 22.5, while there was only one visit in quarter two of 2020. From March 2020 to July 2020 there were only 4 ED visits total. CONCLUSION(S): Assuming the global pandemic was the main influence of GT during March and April 2020, it appears that some IBD-related searches were significantly reduced compared to pre-pandemic levels, while others did not change. It is possible that patients utilized other services like patient portals and telehealth to communicate with providers instead of Google searches. Interestingly, IBD related ED visits were reduced during the peak of the pandemic, which raises the question and concern of how IBD patients managed their disease during this time. Limitations include the non-specificity of querying a search engine which may not reflect the habits of confirmed diagnosed IBD patients. Further research should investigate how patients cared for themselves during the pandemic. It will be important to continue to monitor the trends of IBD patient utilization of the healthcare system as cities and IBD centers start to reopen to safely and effectively deliver care.
ABSTRACT
Introduction: During 3rd year of COVID-19 pandemic there is emerging published and experienced evidence that a significant number of COVID-19 survivors experience long term negative health impact. Post-COVID symptoms arise mostly from impaired function of respiratory tract although in many patients the dysfunction of gastrointestinal tract and liver (among others systems) may persist. Aims & Methods: This prospective single center study was performed from February through October 2021. Adult patients (>18 years) with both asymptomatic PCR confirmed acute SARS-CoV-2 infection and symptomatic (cough, fever or dyspnea) COVID-19 disease patients confirmed by antigen or PCR test were included in the study. Severity of the illness was evaluated according to the National Institute of Health (NIH) guidelines and these were used for distinguishing two main patient groups (with asymptomatic to mild and moderate to severe course of the disease). Patients with negative result of PCR test for SARS-CoV-2 were considered for the control group. Primary data collection was based on the short gastrointestinal symptom questionnaire developed at our department. A brief telephone survey within the patient and control group was performed five to eight months after the initial screening. Patients from the control group, who had been tested positive in the time between initial screening and telephone survey were excluded from the analysis.R ver. 4.0.5 was used for data explorations and analyses. Imbalanced RandomForest (RF) machine-learning algorithm was trained on the data to predict presence/absence of symptoms during acute phase in post-COVID phase. Result(s): 590 patients were included in the study. Of them, 337 patients responded to questions during the telephone survey after 7 months (205 SARS-CoV-2 positive patients, 132 SARS-CoV-2 negative controls). The general presence of gastrointestinal symptoms 208.2 days (153-230 days) after the initial acute SARS-CoV-2 infection was 19% for patients with moderate to serious course of the disease and 7.3% for patients with mild course compared to 3.0% in SARS-CoV-2 negative controls (p<0.001) (table). Persistent diarrhea and abdominal pain are the most prevalent post-COVID gastrointestinal symptoms. To identify possible predictor factors for post COVID gastrointestinal symptoms we performed machine-learning analysis with random forest algorithm with handpicked factors: acute symptoms (diarrhea, abdominal pain, heartburn, bloating, nausea), sex, age and antibiotics administration. Acute diarrhea and antibiotics administration seem to be the strongest predictors for gastrointestinal sequelae with Area under curve (AUC) 0.68. Conclusion(s): Presence of gastrointestinal sequelae 7 months after the initial SARS-CoV-2 infection is significantly higher in patients with moderate to severe course of the acute COVID-19 compared to asymptomatic patients or those with mild course of the disease. Most prevalent post-COVID gastrointestinal symptoms are diarrhea and abdominal pain. The strongest predictors for persistence of these symptoms are antibiotics administration and acute diarrhea during the initial infection.
ABSTRACT
INTRODUCTION: The rate of pediatric patients diagnosed with Sars Cov 2 has increased since the early stages of the pandemic. Gastrointestinal symptoms have been demonstrated to be relatively common in pediatric COVID-19 patients as well as severe complications like PIMS syndrome because of the expression of ACE II in different areas of the digestive tract which serves as a receptor for their entry and infection in the body. During the last months of the omicron variant wave, we observed some gastrointestinal conditions in pediatric patients days after the resolution of the Sars Cov 2 acute infection period, sparking our interest to execute further research and analysis. OBJECTIVE(S): Describe the presence of functional gastrointestinal disorders as a post-covid infection sequel METHODS: We performed a descriptive, cross-sectional, observational, retrospective study, were we recollected the clinical and epidemiological data from the medical records of pediatric patients with a history of Sars cov-2 infection confirmed with positive PCR or antigen (sars cov-2) tests at Hospital Angeles Lomas, Mexico City. We included children from 6 months up to 16 years of age, who presented functional gastrointestinal disorders at a minimum 15 days after the infection that fulfilled Rome IV criteria. We evaluated the frequency and proportion of the qualitative variables;we obtained the arithmetic mean and the standard deviation for the quantitative variables with normal distribution RESULTS: We included data from 30 patients with confirmed covid 19 diseases by positive pcr or antigen (sars cov-2) tests, with a mean age 5.327 +/- 3.8 years Min: 7 months Max: 16 years, with a female predominance of 56.7% vs 43% male patients. During the acute infection by covid, 20% presented respiratory symptoms, 13.3% gastrointestinal symptoms, 36.7% only fever, 3.3% dysgeusia and 26.7% were asymptomatic. Adequate nutritional status was detected in 93% of the patients. The mean days the patients presented manifestations was 32 +/- 14 days, at a minimum 15 days, with a maximum of 63 days, being the most frequent functional gastrointestinal disorders: abdominal pain 90%, bloating 76%, vomit and reflux 33%, diarrhea 30%, constipation 26.7%. There was no weight loss in the patients, the appropriate treatment was given for each case. There was no complication in 90% of the patients, 10% presented acute abdominal pain and were transferred to the emergency room, 1 patient was diagnosed with appendicitis and 2 patients with mesenteric lymphadenitis. CONCLUSION Special attention must be paid to toddler and preschooler patients with Sars Cov 2 infection, regardless of the clinical manifestation in acute infections, mild or asymptomatic, functional gastrointestinal disorders may occur in the first 2 months after a positive PCR test. The ileum and the colon are places in which there is a greater expression of the ACE II, so when the enterocytes are invaded by SARS CoV-2, they may produce alterations in absorption and other mechanisms that could be the cause of these consequences. It is of vital importance that all pediatricians are aware of the consequences of the disease to prevent misdiagnosis.
ABSTRACT
CASE: Ms.X is a 31-year-old female with an unremarkable medical history who presented to the general medicine clinic with palpitations that started 3 days after taking her second dose of Pfizer Covid vaccine. The palpitations ocurred exclusively when standing, with no associated chest pain, dizziness, or presyncope. History is negative for tobacco smoking, drug or alcohol use, and consumption of energy or caffeinated beverages. The physical examination was notable for moist mucous membranes and normal volume examination. Orthostatic vitals were remarkable for an increase in HR by 30 beats with minimal change in BP. EKG showed a normal sinus rhythm, and lab workup inclusive of a CBC, CMP, and TSH was unremarkable. As such, the patient was referred for tilt-table testing. Within 8 minutes of upright tilting, HR was137 from a baseline of 77, and BP was 144/108 from 125/71. A looprecorder was inserted which revealed presence of patient triggered episodes of sinus tachycardia upon standing. The patient was started on propranolol 10 mg every 4-6 hours while awake with almost complete resolution of palpitations. IMPACT/DISCUSSION: The incidence of POTS is 0.2-1% in developed countries, with a 5:1 female-male ratio. It presents with orthostatic symptoms like light-headedness, presyncope, and palpitations. It can occasionally present with non-orthostatic symptoms like nausea, bloating, and diarrhea. The pathophysiology is not well-understood but is postulated to be due to an autoimmune disorder, abnormally increased sympathetic activity, and/or sympathetic denervation leading to central hypovolemia and reflex tachycardia. It is a diagnosis of exclusion, but table-tilt test is used to help confirm it. The onset is typically precipitated by immunological stressors like viral infections, vaccination, and pregnancy. Recently, several case reports have been published describing POTS following infection with COVID-19 infection. This was described as long-COVID postural tachycardia syndrome by the American Autonomic Society. However, the association of POTS with COVID-19 vaccine is unclear. Only one case report was published describing the development of POTS after COVID-19 mRNA vaccine. Information relating to this remain limited, and approach to diagnosis and treatment is variable. Our understanding of this condition in relation to vaccination is mostly extrapolated from previously published reports describing it in relation to HPV vaccine. As more people continue to take the vaccine, physicians should be alert to the diagnosis. CONCLUSION: POTS is a frequently underdiagnosed or misdiagnosed disorder. It is characterized by an increase in HR by 30 within 10 minutes of standing . In rare instances, it has been described as a postvaccination adverse immune phenomena, and more recently related to mRNA COVID-19 vaccination. Increased recognition, diagnosis, and reporting will contribute to better understanding and treatment.
ABSTRACT
Background: Optimizing management of gastroesophageal reflux disease (GERD) is important to preserve graft function after lung transplantation as patients with GERD are at higher risk of rejection. Patients with COVID-19 associated respiratory failure undergoing lung transplantation is an emerging subset of patients in which GERD pre- or post-transplant is not well characterized. Aim: To evaluate the prevalence and adverse effects of GERD both pre- and post-transplant in patients undergoing lung transplantation for severe COVID-19 infection. Methods: A retrospective review was conducted at a single academic medical center with a large multi-organ transplant program. All patients undergoing lung transplant due to COVID-19 from 2020-2021 were included in the study, with attention to pre- and post-operative physiological testing for GERD. Results: Seventeen patients were identified who had undergone lung transplant for COVID-19. All patients were male;52.9% (9/17) were Hispanic, 35.3% (6/17) Caucasian and 11.8% (2/17) Black. Median age was 50 (24- 70 years) with median time to transplant from documented infection of 131 days. A prehospitalization GERD diagnosis was found in 29.4% (5/17) patients, and two patients (11.8%) were taking prescribed proton-pump inhibitor (PPI) prior to their COVID-19 associated hospitalization. No patient underwent pre-transplant GERD testing, although three patients did undergo upper endoscopy for GI bleeding prior to transplant. Post-transplant, all patients were immediately treated with PPI per institutional protocol. 70.5% (12/17) patients reported post-transplant foregut symptoms including heartburn, regurgitation, dysphagia, early satiety, abdominal bloating/cramping, nausea and vomiting. All 17 patients had at least one symptomdriven foregut study such as a gastric emptying study, barium esophagram, upper endoscopy, esophageal manometry or pH testing. Three patients were referred for anti-reflux surgery (ARS) based on results of testing, including delayed gastric emptying, abnormal pH testing and bronchoscopy findings concerning for aspiration pneumonia. All three underwent Toupet fundoplication with or without hiatal hernia repair;one was performed early (< 3 mo) posttransplant, two occurred late (> 6 mo), and none had complications or symptom-based recurrence of reflux. Discussion: In this large single-center series of COVID-19 associated respiratory failure and lung transplant, pre-operative reflux testing could not be performed;however, post-transplant GERD symptoms were still routinely assessed and evaluated, prompting management with ARS in a small subset of patients, both early and late posttransplant, with resolution of GERD symptoms. Long-term outcomes of this unique group and comparison with others requiring transplant will necessitate further investigation to assess impact of GERD on allograft dysfunction.
ABSTRACT
BACKGROUND: The effect of dietary collagen on managing digestive symptoms is currently lacking in the literature. OBJECTIVE: To gain a better understanding of this issue, we conducted a 2-phase mixed methods study. METHODS: Phase 1 was a mixed methods design to explore current attitude and practice among consumers and health care practitioners. The findings were used to design an 8-week phase 2 digital study called Gutme! conducted in the United States in healthy female volunteers (BMI>25 kg/m2). Our aim was, first, to determine the feasibility of conducting a fully digital mixed methods study; second, the study explored the effect of an 8-week daily supplementation of 20 g dietary collagen peptide (Peptan) on digestive symptoms. Phase 2 was a prospective, open-label, longitudinal, single-arm study. Participation involved 2 weeks of baseline tracking (digestive symptoms, mood, stool, and lifestyle) using an app, followed by 8 weeks of tracking and taking 20 g collagen peptide supplement split into 2 dosages per day. Participants were required to complete a web-based symptom questionnaire at baseline, week 2, and week 8, as well as participate in 2 scheduled video interviews. RESULTS: Phase 1 revealed that consumer awareness of collagen for digestive health is low (64/204, 31.4%). Among the dietitians prescribing collagen for their patients, the most common dosage was 20 g a day with notable effects after 6 weeks of intake. Within the phase 2 study, of the 40 recruited participants, 14 (35%) completed the full course of supplementation. The findings indicate that 93% (13/14) of those who completed the study experienced a reduction in digestive symptoms, which included bloating. CONCLUSIONS: A mixed methods digital study design is feasible and acceptable for collecting relevant data in a real-life setting. The use of a 20 g daily collagen peptide supplement may reduce bloating and improve mild digestive symptoms in otherwise healthy female adults in the absence of any other dietary or lifestyle interventions. TRIAL REGISTRATION: ClinicalTrials.gov NCT04245254; https://clinicaltrials.gov/ct2/show/NCT04245254.
ABSTRACT
Background: The diversity demography of coronavirus disease 2019 (COVID-19) has prompted us to collect data in our workplace. These data are essential because they can serve as a data bank of demographics in one big hospital in East Java. We analyzed patients' characteristics with COVID-19 admitted to the Intensive Care Unit (ICU) Special Hospital for Infections, Airlangga University, Surabaya. Methods: Retrospective study from medical record of 180 patients with confirmed COVID-19 admitted to the ICU Special Hospital for Infections, Airlangga University of Surabaya between April-September 2020. Results: Most of the patients were male (67.2%), with median age was 55 (22-83) years. The body mass index (BMI) data consisted of normal (48.9%), overweight (39.4%), obesity class I 7.8%, obesity class II 1.1%, obesity class III 0.6%, and underweight 2.2%. We found severe acute respiratory distress syndrome (ARDS) in 63.9%. The use of invasive mechanical ventilation was 74% of the total patients. Most of the . patients (85%) had comorbidity: hypertension, diabetes mellitus, and geriatrics. The average length of stay in the ICU was 8.5 days. We trans-ferred 29% of patients to a low-care ward, and 66.7% died. We identified gastrointestinal symptoms on admission to the ICU were 43.3%, pre-dominantly by nausea and vomiting. Forty-six point seven percent of patients with gastrointestinal symptoms during hospitalization consisted of gastric retention and diarrhea, some with hematin. Conclusion: The demographic data we present above are limited in our area. The demographic data of COVID-19 patients in other places may be different from the information we obtained. However, data like this may represent the patient's condition in areas similar to ours. Besides, this data can warn that the patient's condition, as in our data, requires special attention. It is necessary to add data from all corners of Indonesia to represent the demographic data of COVID-19 patients in Indonesia.
ABSTRACT
Background/Aims: Digestive symptoms are common in patients with COVID-19. Neverthe-less, the evidence available so far is based on retrospective and observational studies. This prospective multicenter cohort study aimed to describe the frequency, intensity, evolution, and impact of digestive symptoms and complications, during hospitalization and after dis-charge, of patients with COVID-19. Methods: Patients hospitalized due to COVID-19 (posi-tive PCR for SARS-CoV-2) from May to August 2020, were prospectively recruited in 31 centers. Follow-up included the period between admission and 15 days after discharge. Results: 829 patients (mean age 56.7±17.9 years;42% of females) were enrolled in this study. Of these, 7.2% were active smokers and the mean BMI was 29.1±5.7. Proton pump inhibitors were used by 21.5% (n=178). The most prevalent symptoms on admission were diarrhea (39.4%), nausea (27.4%), and abdominal pain (20.7%). Anorexia, a non-specific symptom, was present in 49.8% of hospitalized patients. At discharge and 15 days after discharge, most symptoms resolved, returning to the baseline prevalence of patients (<5%). Digestive complications during admission were infrequent, except for liver injury defined as hypertransaminasemia which was present in 267 patients (32.3%). The mean length of hospital stay was 8 days (5-12) and 13.6% needed ICU admission. Death happened in 5.2%of patients. On multivariate analysis, diarrhea on admission was associated with a shorter hospital stay (<10 days) ORa 0.508 (0.350-0.739) p=0.000. During hospitalization, diarrhea, constipation, and abdominal bloating were associated with shorter hospital stay ORa 0.531 (0.298-0.946) p=0.032, ORa 0.384 (0.167-0.885) p=0.025, ORa 0.163 (0.057-0.466) p= 0.00, respectively.Odynophagia and dysphagia during hospitalization were associated with a higher need for ICU admission, ORa 6.518 (2.255-18.835) p=0.001 and ORa 4.035 (1.453-11.204) p=0.007, respectively. Liver injury during hospitalization was associated with a higher hospital stay (>10 days) ORa 1.442 (1.019-2.041) p=0.039. In the linear regression analysis, the set of GI symptoms and complications, along with age, comorbidity, and respiratory symptoms, were able to predict 43% (R2 0.43) of the observed variability in the speed of ICU admission;in this case, digestive symptoms slowed it down (more days until ICU admission). Conclusions: Gastrointestinal manifestations of COVID-19 are common in hospitalized patients, while complications are infrequent. Gastrointestinal symptoms seemed to predict a shorter hospital stay and slower speed of ICU admission. These tend to resolve to their baseline prevalence 15 days after discharge, while elevated transaminases were associated with a longer hospital stay. Odynophagia and dysphagia during hospitaliza-tion were associated with an increased need for ICU admission.
ABSTRACT
Background: Irritable bowel syndrome with constipation (IBS-C) is a chronic disorder of gut-brain interaction (DGBI) that has a significant negative impact on patients. The objective of this study was to examine disease burden and care-seeking behavior of IBS-C patients during the COVID-19 pandemic. Methods: A cross-sectional, on-line, general health survey collected data on US adults aged >18 from Aug – Oct 2020. IBS-C patients were defined using Rome IV criteria for IBS-C and matched 1:1 by age, sex, region, and comorbidity score to the general population. Health outcomes comparing IBS-C patients vs controls included anxiety (using Generalized Anxiety Disorder scale [GAD-7]), depression (using Patient Health Questionnaire 9 [PHQ-9]), health-related quality of life (HRQoL) (using Veterans RAND 12-item Health Survey [VR-12]), and work productivity using study-specific questions. Mean frequencies were compared with ANOVA and proportions with chi-square tests. For IBS-C patients, care-seeking behavior included healthcare visits in the past 12 months, canceled visits due to COVID-19, and medication use (prescription vs over-the-counter (OTC)). Commonly reported bothersome symptoms and the impact of COVID-19 on the worsening of IBS-C symptoms were also assessed descriptively. Results: Of 7,214 survey participants, 138 met Rome IV criteria for IBS-C. Matching resulted in a sample of 130 IBS-C patients and 130 controls. Mean age of IBS-C patients was 45.1 (SD 15.1) years, with the majority being female (79.2%) and white (82.3%). IBS-C patients had a significantly higher proportion of moderate-to-severe anxiety and depression and significantly lower HRQoL versus controls (see Table). Absenteeism and presenteeism in the past 7 days were also significantly higher among IBS-C patients vs controls. 53.4% percent of IBS-C patients sought care from a healthcare provider in the past year for their IBS symptoms and nearly a quarter of IBS-C patients reported cancelling healthcare visits due to COVID-19. 25.4% of IBS-C patients reported taking a prescription medication whereas 68.5% reported currently taking an OTC for their IBS-C symptoms. The most common bothersome symptoms in the past 7 days included abdominal discomfort, abdominal pain, straining, abdominal bloating and incomplete bowel movements. Over a third of IBS-C patients indicated their symptoms worsened during the COVID-19 pandemic. Conclusions: There remains a considerable disease burden and unmet need for IBS-C patients, with patients suffering from multiple bothersome symptoms and low rates of prescription medication use. COVID-19 seems to have worsened IBS symptoms for many patients (Table Presented) (Table Presented)